More than 1 million prescriptions for the COVID-19 antiviral pills Lagevrio and Paxlovid were dispensed between late December 2021 and May 2022, but dispensing rates were lowest in the most socially and economically disadvantaged communities, according to a study released today by the Centers for Disease Control and Prevention. In a separate study of electronic health records from Kaiser Permanente Southern California over the period, fewer than 1% of patients aged 12 and older who received Paxlovid to treat mild-to-moderate COVID-19 had a COVID-19-related hospitalization or emergency department visit in the next five to 15 days. CDC said the studies “highlight the importance of ensuring access to oral antiviral medicine in treating COVID-19, a key strategy in preventing hospitalization and death.”

Related News Articles

Headline
The Food and Drug Administration today authorized the Moderna and Pfizer bivalent COVID-19 vaccines for emergency use in children as young as 6 months old.…
#HealthCareInnovation Thursday Blog
Early on in my professional journey as a physician, I had a calling to work with infectious diseases. Little did I know then how big a role this medical…
Headline
On Dec. 15, the Department of Health and Human Services will stop collecting hospitals’ COVID-19 data through the TeleTracking portal and begin collecting the…
Headline
The Institute for Healthcare Improvement today launched Rise to Health: A National Coalition for Equity in Health Care, whose founding collaborators include…
Headline
The latest AHA podcast on leading initiatives to transform care and advance equity looks at Jefferson Health’s success in expanding diversity at the…
Headline
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., today encouraged all eligible Americans to get vaccinated against the flu and…